关键词：糖尿病性神经病变；神经紊乱；神经轴突损伤；神经动作电位；神经元；信号传输
摘 要：Diabetic neuropathy is a nerve disorder associated with diabetes. As a result of diabetic neuropathy, axonal damage decreases nerve action potential , thereby inhibiting neuronal signal transmission. Diabetic neuropathy is characterized by progressive damage to the myelin sheath, which slows down nerve conduction velocity. About 60-70 percent of diabetic patients develop neuropathy, with a considerable number of patients remaining undiagnosed during the initial years of progression. Hence, disease management should start with the initial diagnosis of diabetes. Diabetic neuropathy treatment involves lowering blood glucose levels (keeping it within the normal range) to prevent further nerve damage and treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture, or other relaxation techniques, can also be used to provide relief to patients.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report.

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

15.1 Competitive Scenario

15.1.1 Key News

15.1.2 Mergers and Acquisitions

15.2 Vendors Analysis 2013

15.3 Other Prominent Vendors

16. Key Vendor Analysis

16.1 Eli Lilly and Co.

16.1.1 Business Overview

16.1.2 Business Segmentation

16.1.3 Key Information

16.1.4 SWOT Analysis

16.2 Janssen Pharmaceuticals Inc

16.2.1 Business Overview

16.2.2 Key Information

16.2.3 SWOT Analysis

16.3 Pfizer Inc.

16.3.1 Business Overview

16.3.2 Key Information

16.3.3 SWOT Analysis

17. Pipeline Analysis

17.1 Phase III Analysis

17.2 Phase II Analysis

17.3 Phase I Analysis

17.4 Discontinued Projects

17.5 Projects on Hold

17.6 Promising Pipeline Molecules

17.6.1 Phase III Promising Pipeline Molecules

17.6.2 Phase II Promising Pipeline Molecules

17.7 Other First-in-class Pipeline Molecules

18. Other Reports in this Series